Merck & Co., Inc. (NYSE:MRK)‘s stock had its “hold” rating reaffirmed by research analysts at Cowen and Company in a report released on Friday. They currently have a $70.00 price target on the stock. Cowen and Company’s price target points to a potential upside of 24.87% from the company’s current price.
A number of other equities analysts have also recently commented on the company. Berenberg Bank reaffirmed a “hold” rating on shares of Merck & Co. in a report on Wednesday. Jefferies Group LLC cut Merck & Co. from a “hold” rating to an “underperform” rating in a report on Wednesday. BMO Capital Markets set a $68.00 target price on Merck & Co. and gave the stock a “buy” rating in a report on Monday, October 30th. Leerink Swann decreased their target price on Merck & Co. from $70.00 to $69.00 and set a “market perform” rating on the stock in a report on Monday, October 30th. Finally, Citigroup Inc. raised Merck & Co. to a “buy” rating in a report on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $67.07.
Merck & Co. (NYSE:MRK) opened at $56.06 on Friday. Merck & Co. has a twelve month low of $54.41 and a twelve month high of $66.80. The company has a market capitalization of $153,333.30, a price-to-earnings ratio of 14.41, a P/E/G ratio of 2.41 and a beta of 0.78. The company has a quick ratio of 1.21, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.
Merck & Co. (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. The company had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period in the prior year, the business posted $1.07 earnings per share. Merck & Co.’s revenue for the quarter was down 2.0% compared to the same quarter last year. analysts anticipate that Merck & Co. will post 3.95 earnings per share for the current year.
Several hedge funds have recently modified their holdings of MRK. Vanguard Group Inc. increased its holdings in shares of Merck & Co. by 1.7% in the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock worth $12,442,709,000 after purchasing an additional 3,312,459 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Merck & Co. by 71.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 6,281,855 shares of the company’s stock worth $402,604,000 after purchasing an additional 2,618,435 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Merck & Co. by 40.4% in the second quarter. Principal Financial Group Inc. now owns 8,012,726 shares of the company’s stock worth $513,535,000 after purchasing an additional 2,304,142 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of Merck & Co. by 70.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock worth $353,841,000 after purchasing an additional 2,300,200 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Merck & Co. by 36.3% in the second quarter. Parametric Portfolio Associates LLC now owns 7,766,906 shares of the company’s stock worth $497,774,000 after purchasing an additional 2,070,487 shares during the last quarter. 72.86% of the stock is currently owned by hedge funds and other institutional investors.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Co. Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Co. Inc. and related companies.